Regulatory & Reimbursement
FDA Output, March 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in March 2026. Updated March 5.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
The Digest
The Digest: February 2026
In this month's news, Medtronic gets clearance for fast-acting insulin pump, VB Spine to buy SpineHawk, strategic profit forecasts vary, and more.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Pathways’ Pick of the Week
Pathways' Pick of the Week: FDA Taps Digital Lead
Rick Abramson picked to lead FDA’s Digital Health Center of Excellence. Excerpted from Pathways’ Picks Febraury 25: Tariff Topsy-Turvy, CPT Panel Decisions, Reliance in South Africa.